BioWorld

Jan. 4, 2008

View Archived Issues

Rights to Schizophrenia Drug Worth up to $702M for Addex

Swiss biotech Addex Pharmaceuticals has granted rights to Merck & Co. Inc. to develop ADX63365, an investigational treatment for schizophrenia, in a deal potentially worth $702 million. (BioWorld Today) Read More

Crucell Signs Sanofi Pasteur in $113M Rabies Antibodies Deal

Read More

ImmunoGen Entering TAP Cancer Deal with Centocor

Read More

Gelesis Closes $16M Series A to Fund its Obesity Program

Read More

QuatRx Meets all Endpoints in Ophena Phase III Trial

Read More

Other News To Note

Read More

Clinic Roundup

Read More